MedTrace Logo

Characterisation of the Biochemical Profile and Physiology of the Coronary Circulation in Takotsubo Syndrome

NCT06669962 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-11-01

No results posted yet for this study

Summary

Consecutive consenting patients over the age of 18 years diagnosed with Takotsubo syndrome according to the position statement of the European Journal of Heart Failure (2016) will be included in the study. The primary endpoint is to evaluate the incidence of coronary microcirculation dysfunction and its correlation with the clinical presentation and the prognosis in patients with TAKO-Tsubo syndrome. Secondary endpoints will be to assess the incidence of in-hospital mortality, the prevalence of cardiogenic shock, the correlation between the levels of biomarkers analyzed, microvascular dysfunction, perceived quality of life, and angina severity during hospitalization and at subsequent follow-ups, and the influence of knowledge of the level of microvascular dysfunction on clinical management and prescribed therapies. Enrolment: 2 years, follow-up: 1 month and 1 year. Total: 3 years.

Conditions

  • Tako Tsubo Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

Study of coronary microcirculation and biomarkers of microvascular dysfunction

Patients with tako-tsubo syndrome will undergo to coronary angiography, ventriculography and assessment of physiological indexes of coronary circulation as per clinical practice

Sponsors & Collaborators

  • A.O.U. Città della Salute e della Scienza

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2026-06-27
Completion
2027-06-27

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06669962 on ClinicalTrials.gov